Last updated on May 2019

A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3K-delta Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

 

Clinical Study Identifier: TX203807

Find a site near you

Start Over

Calvary North Adelaide Hospital

Located in: North Adelaide, Australia
3.98miles
  Connect »

ROYAL ADELAIDE HOSPITAL

Located in: Adelaide, Australia
5.29miles
  Connect »